VEGF promotes tumorigenesis and angiogenesis of human glioblastoma stem cells. 2007

Naoki Oka, and Akio Soeda, and Akihito Inagaki, and Masafumi Onodera, and Hidekazu Maruyama, and Akira Hara, and Takahiro Kunisada, and Hideki Mori, and Toru Iwama
Department of Neurosurgery, Gifu University School of Medicine, 1-1 Yanagido, Gifu City, Gifu 501-1194, Japan.

There is increasing evidence for the presence of cancer stem cells (CSCs) in malignant brain tumors, and these CSCs may play a pivotal role in tumor initiation, growth, and recurrence. Vascular endothelial growth factor (VEGF) promotes the proliferation of vascular endothelial cells (VECs) and the neurogenesis of neural stem cells. Using CSCs derived from human glioblastomas and a retrovirus expressing VEGF, we examined the effects of VEGF on the properties of CSCs in vitro and in vivo. Although VEGF did not affect the property of CSCs in vitro, the injection of mouse brains with VEGF-expressing CSCs led to the massive expansion of vascular-rich GBM, tumor-associated hemorrhage, and high morbidity, suggesting that VEGF promoted tumorigenesis via angiogenesis. These results revealed that VEGF induced the proliferation of VEC in the vascular-rich tumor environment, the so-called stem cell niche.

UI MeSH Term Description Entries
D009389 Neovascularization, Pathologic A pathologic process consisting of the proliferation of blood vessels in abnormal tissues or in abnormal positions. Angiogenesis, Pathologic,Angiogenesis, Pathological,Neovascularization, Pathological,Pathologic Angiogenesis,Pathologic Neovascularization,Pathological Angiogenesis,Pathological Neovascularization
D005909 Glioblastoma A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures. Astrocytoma, Grade IV,Giant Cell Glioblastoma,Glioblastoma Multiforme,Astrocytomas, Grade IV,Giant Cell Glioblastomas,Glioblastoma, Giant Cell,Glioblastomas,Glioblastomas, Giant Cell,Grade IV Astrocytoma,Grade IV Astrocytomas
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D014411 Neoplastic Stem Cells Highly proliferative, self-renewing, and colony-forming stem cells which give rise to NEOPLASMS. Cancer Stem Cells,Colony-Forming Units, Neoplastic,Stem Cells, Neoplastic,Tumor Stem Cells,Neoplastic Colony-Forming Units,Tumor Initiating Cells,Cancer Stem Cell,Cell, Cancer Stem,Cell, Neoplastic Stem,Cell, Tumor Initiating,Cell, Tumor Stem,Cells, Cancer Stem,Cells, Neoplastic Stem,Cells, Tumor Initiating,Cells, Tumor Stem,Colony Forming Units, Neoplastic,Colony-Forming Unit, Neoplastic,Initiating Cell, Tumor,Initiating Cells, Tumor,Neoplastic Colony Forming Units,Neoplastic Colony-Forming Unit,Neoplastic Stem Cell,Stem Cell, Cancer,Stem Cell, Neoplastic,Stem Cell, Tumor,Stem Cells, Cancer,Stem Cells, Tumor,Tumor Initiating Cell,Tumor Stem Cell,Unit, Neoplastic Colony-Forming,Units, Neoplastic Colony-Forming
D016513 Mice, SCID Mice homozygous for the mutant autosomal recessive gene "scid" which is located on the centromeric end of chromosome 16. These mice lack mature, functional lymphocytes and are thus highly susceptible to lethal opportunistic infections if not chronically treated with antibiotics. The lack of B- and T-cell immunity resembles severe combined immunodeficiency (SCID) syndrome in human infants. SCID mice are useful as animal models since they are receptive to implantation of a human immune system producing SCID-human (SCID-hu) hematochimeric mice. SCID Mice,SCID-hu Mice,Severe Combined Immunodeficient Mice,Immunodeficient Mice, Severe Combined,Mouse, SCID,Mouse, SCID-hu,Mice, SCID-hu,Mouse, SCID hu,SCID Mouse,SCID hu Mice,SCID-hu Mouse
D016688 Mice, Inbred NOD A strain of non-obese diabetic mice developed in Japan that has been widely studied as a model for T-cell-dependent autoimmune insulin-dependent diabetes mellitus in which insulitis is a major histopathologic feature, and in which genetic susceptibility is strongly MHC-linked. Non-Obese Diabetic Mice,Mice, NOD,Mouse, Inbred NOD,Mouse, NOD,Non-Obese Diabetic Mouse,Nonobese Diabetic Mice,Nonobese Diabetic Mouse,Diabetic Mice, Non-Obese,Diabetic Mice, Nonobese,Diabetic Mouse, Non-Obese,Diabetic Mouse, Nonobese,Inbred NOD Mice,Inbred NOD Mouse,Mice, Non-Obese Diabetic,Mice, Nonobese Diabetic,Mouse, Non-Obese Diabetic,Mouse, Nonobese Diabetic,NOD Mice,NOD Mice, Inbred,NOD Mouse,NOD Mouse, Inbred,Non Obese Diabetic Mice,Non Obese Diabetic Mouse
D042461 Vascular Endothelial Growth Factor A The original member of the family of endothelial cell growth factors referred to as VASCULAR ENDOTHELIAL GROWTH FACTORS. Vascular endothelial growth factor-A was originally isolated from tumor cells and referred to as "tumor angiogenesis factor" and "vascular permeability factor". Although expressed at high levels in certain tumor-derived cells it is produced by a wide variety of cell types. In addition to stimulating vascular growth and vascular permeability it may play a role in stimulating VASODILATION via NITRIC OXIDE-dependent pathways. Alternative splicing of the mRNA for vascular endothelial growth factor A results in several isoforms of the protein being produced. Vascular Endothelial Growth Factor,Vascular Endothelial Growth Factor-A,GD-VEGF,Glioma-Derived Vascular Endothelial Cell Growth Factor,VEGF,VEGF-A,Vascular Permeability Factor,Vasculotropin,Glioma Derived Vascular Endothelial Cell Growth Factor,Permeability Factor, Vascular
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines
D049109 Cell Proliferation All of the processes involved in increasing CELL NUMBER including CELL DIVISION. Cell Growth in Number,Cellular Proliferation,Cell Multiplication,Cell Number Growth,Growth, Cell Number,Multiplication, Cell,Number Growth, Cell,Proliferation, Cell,Proliferation, Cellular

Related Publications

Naoki Oka, and Akio Soeda, and Akihito Inagaki, and Masafumi Onodera, and Hidekazu Maruyama, and Akira Hara, and Takahiro Kunisada, and Hideki Mori, and Toru Iwama
January 2013, TheScientificWorldJournal,
Naoki Oka, and Akio Soeda, and Akihito Inagaki, and Masafumi Onodera, and Hidekazu Maruyama, and Akira Hara, and Takahiro Kunisada, and Hideki Mori, and Toru Iwama
May 2006, British journal of cancer,
Naoki Oka, and Akio Soeda, and Akihito Inagaki, and Masafumi Onodera, and Hidekazu Maruyama, and Akira Hara, and Takahiro Kunisada, and Hideki Mori, and Toru Iwama
January 2015, Brain tumor pathology,
Naoki Oka, and Akio Soeda, and Akihito Inagaki, and Masafumi Onodera, and Hidekazu Maruyama, and Akira Hara, and Takahiro Kunisada, and Hideki Mori, and Toru Iwama
November 2017, Experimental cell research,
Naoki Oka, and Akio Soeda, and Akihito Inagaki, and Masafumi Onodera, and Hidekazu Maruyama, and Akira Hara, and Takahiro Kunisada, and Hideki Mori, and Toru Iwama
July 2013, Oncotarget,
Naoki Oka, and Akio Soeda, and Akihito Inagaki, and Masafumi Onodera, and Hidekazu Maruyama, and Akira Hara, and Takahiro Kunisada, and Hideki Mori, and Toru Iwama
November 2011, Nature reviews. Cancer,
Naoki Oka, and Akio Soeda, and Akihito Inagaki, and Masafumi Onodera, and Hidekazu Maruyama, and Akira Hara, and Takahiro Kunisada, and Hideki Mori, and Toru Iwama
October 2023, Molecular biology reports,
Naoki Oka, and Akio Soeda, and Akihito Inagaki, and Masafumi Onodera, and Hidekazu Maruyama, and Akira Hara, and Takahiro Kunisada, and Hideki Mori, and Toru Iwama
September 2012, Microvascular research,
Naoki Oka, and Akio Soeda, and Akihito Inagaki, and Masafumi Onodera, and Hidekazu Maruyama, and Akira Hara, and Takahiro Kunisada, and Hideki Mori, and Toru Iwama
January 2015, PloS one,
Naoki Oka, and Akio Soeda, and Akihito Inagaki, and Masafumi Onodera, and Hidekazu Maruyama, and Akira Hara, and Takahiro Kunisada, and Hideki Mori, and Toru Iwama
April 2019, The international journal of biochemistry & cell biology,
Copied contents to your clipboard!